{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:06:44Z","timestamp":1788577604375,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ARTC-Sud"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11060-022-04032-5","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T06:03:53Z","timestamp":1656396233000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma"],"prefix":"10.1007","volume":"159","author":[{"given":"Axel","family":"Berthelot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Harlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Petrirena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Barri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Appay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Tabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"4032_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/neuonc\/noy192","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Rubenstein JL, DeAngelis LM et al (2019) Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 21:296\u2013305. https:\/\/doi.org\/10.1093\/neuonc\/noy192","journal-title":"Neuro Oncol"},{"key":"4032_CR2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"4032_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","volume":"85","author":"AMP Omuro","year":"2007","unstructured":"Omuro AMP, Taillandier L, Chinot O et al (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207\u2013211. https:\/\/doi.org\/10.1007\/s11060-007-9397-0","journal-title":"J Neurooncol"},{"key":"4032_CR4","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027\u2013e1039. https:\/\/doi.org\/10.1212\/WNL.0000000000008900","journal-title":"Neurology"},{"key":"4032_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/JCO.18.00306","journal-title":"J Clin Oncol"},{"key":"4032_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M et al (2019) Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol 30:621\u2013628. https:\/\/doi.org\/10.1093\/annonc\/mdz032","journal-title":"Ann Oncol"},{"key":"4032_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117:121\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","journal-title":"Eur J Cancer"},{"key":"4032_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00262-020-02575-y","volume":"69","author":"L Marcelis","year":"2020","unstructured":"Marcelis L, Antoranz A, Delsupehe A-M et al (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751\u20131766. https:\/\/doi.org\/10.1007\/s00262-020-02575-y","journal-title":"Cancer Immunol Immunother"},{"key":"4032_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJM Ferreri","year":"2003","unstructured":"Ferreri AJM, Blay J-Y, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266\u2013272. https:\/\/doi.org\/10.1200\/JCO.2003.09.139","journal-title":"J Clin Oncol"},{"key":"4032_CR10","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711\u20135715. https:\/\/doi.org\/10.1200\/JCO.2006.08.2941","journal-title":"J Clin Oncol"},{"key":"4032_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2012.076075","volume":"98","author":"E Schorb","year":"2013","unstructured":"Schorb E, Kasenda B, Atta J et al (2013) Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 98:765\u2013770. https:\/\/doi.org\/10.3324\/haematol.2012.076075","journal-title":"Haematologica"},{"key":"4032_CR12","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cam4.2872","volume":"9","author":"C-J Liu","year":"2020","unstructured":"Liu C-J, Lin S-Y, Yang C-F et al (2020) A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med 9:2134\u20132145. https:\/\/doi.org\/10.1002\/cam4.2872","journal-title":"Cancer Med"},{"key":"4032_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708784","volume":"11","author":"Y Lu","year":"2021","unstructured":"Lu Y, Yu J, Gong W et al (2021) An Immune-Clinical Prognostic Index (ICPI) for patients with de novo follicular lymphoma treated With R-CHOP\/CHOP chemotherapy. Front Oncol 11:708784. https:\/\/doi.org\/10.3389\/fonc.2021.708784","journal-title":"Front Oncol"},{"key":"4032_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","volume":"61","author":"Y Gu","year":"2020","unstructured":"Gu Y, Jin Y, Ding J et al (2020) Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma 61:1869\u20131876. https:\/\/doi.org\/10.1080\/10428194.2020.1751840","journal-title":"Leuk Lymphoma"},{"key":"4032_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00277-021-04474-3","volume":"100","author":"X Cao","year":"2021","unstructured":"Cao X, Kong Y-L, Wang L et al (2021) Circulating low CD4+\/CD8+ ratio is associated with poor prognosis in Waldenstrom macroglobulinemia patients. Ann Hematol 100:995\u20131002. https:\/\/doi.org\/10.1007\/s00277-021-04474-3","journal-title":"Ann Hematol"},{"key":"4032_CR16","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/cas.13020","volume":"107","author":"X-Y Zhang","year":"2016","unstructured":"Zhang X-Y, Xu J, Zhu H-Y et al (2016) Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci 107:1471\u20131476. https:\/\/doi.org\/10.1111\/cas.13020","journal-title":"Cancer Sci"},{"key":"4032_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2018.12.003","volume":"131","author":"Y An","year":"2019","unstructured":"An Y, Jiang W, Andraos TY et al (2019) Multi-institutional Investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2018.12.003","journal-title":"Radiother Oncol"},{"key":"4032_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639644","volume":"11","author":"Q Luo","year":"2021","unstructured":"Luo Q, Yang C, Fu C et al (2021) Prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy. Front Oncol 11:639644. https:\/\/doi.org\/10.3389\/fonc.2021.639644","journal-title":"Front Oncol"},{"key":"4032_CR19","doi-asserted-by":"publisher","first-page":"74975","DOI":"10.18632\/oncotarget.20480","volume":"8","author":"J Jung","year":"2017","unstructured":"Jung J, Lee H, Yun T et al (2017) Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary. Oncotarget 8:74975\u201374986. https:\/\/doi.org\/10.18632\/oncotarget.20480","journal-title":"Oncotarget"},{"key":"4032_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176008","volume":"12","author":"J Wang","year":"2017","unstructured":"Wang J, Zhou X, Liu Y et al (2017) Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: a meta-analysis. PLoS ONE 12:e0176008. https:\/\/doi.org\/10.1371\/journal.pone.0176008","journal-title":"PLoS ONE"},{"key":"4032_CR21","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1634\/theoncologist.2018-0629","volume":"24","author":"M Le","year":"2019","unstructured":"Le M, Garcilazo Y, Ib\u00e1\u00f1ez-Juli\u00e1 M-J et al (2019) Pretreatment hemoglobin as an independent prognostic factor in primary central nervous system lymphomas. Oncologist 24:e898\u2013e904. https:\/\/doi.org\/10.1634\/theoncologist.2018-0629","journal-title":"Oncologist"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04032-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:25:18Z","timestamp":1659104718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04032-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}